Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria.
Case series
Immune checkpoint inhibitors
Left ventricular function
Magnetic resonance imaging
Myocarditis
Journal
European heart journal. Case reports
ISSN: 2514-2119
Titre abrégé: Eur Heart J Case Rep
Pays: England
ID NLM: 101730741
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
09
02
2021
revised:
27
04
2021
accepted:
24
11
2021
entrez:
26
1
2022
pubmed:
27
1
2022
medline:
27
1
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) have improved outcomes for many types of cancer. However, ICI therapies are associated with the development of myocarditis, an immune-mediated adverse event associated with a high mortality rate. Therefore, prompt diagnosis and early intervention are of outmost importance. There is limited data on the application of cardiovascular magnetic resonance (CMR)-based modified Lake Louise Criteria (mLLC) with the use of relaxometry techniques for the diagnosis of ICI myocarditis. Four cancer patients undergoing ICI treatment presented with various clinical symptoms and troponin elevation to emergency/ambulatory clinics within 10-21 days after ICI initiation. On the suspicion of possible ICI-related myocarditis all patients underwent CMR within a few days after admission. Applying mLLC including relaxometry techniques, all patients met 'non-ischaemic injury criteria', while 3/4 patients met 'oedema criteria'. In most patients, quantitative mapping revealed substantially increased T1 values, while T2 values were only mildly increased or normal. In two patients with follow-up, CMR demonstrated improvement in findings after immunosuppressive treatment. However, there was only limited agreement between the degree of high-sensitive troponin levels and T1/T2 levels. The application of mLLC with T1/T2 mapping appears useful in the CMR diagnosis of acute ICI myocarditis with non-ischaemic myocardial injury criteria being the most common finding. The sensitivity of native T1 appears higher than T2 mapping in the acute diagnosis as well as in the assessment of treatment response. As troponin elevations may persist for some time with ICI myocarditis, CMR may represent an alternate strategy to monitor treatment response.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors (ICIs) have improved outcomes for many types of cancer. However, ICI therapies are associated with the development of myocarditis, an immune-mediated adverse event associated with a high mortality rate. Therefore, prompt diagnosis and early intervention are of outmost importance. There is limited data on the application of cardiovascular magnetic resonance (CMR)-based modified Lake Louise Criteria (mLLC) with the use of relaxometry techniques for the diagnosis of ICI myocarditis.
CASE SUMMARY
METHODS
Four cancer patients undergoing ICI treatment presented with various clinical symptoms and troponin elevation to emergency/ambulatory clinics within 10-21 days after ICI initiation. On the suspicion of possible ICI-related myocarditis all patients underwent CMR within a few days after admission. Applying mLLC including relaxometry techniques, all patients met 'non-ischaemic injury criteria', while 3/4 patients met 'oedema criteria'. In most patients, quantitative mapping revealed substantially increased T1 values, while T2 values were only mildly increased or normal. In two patients with follow-up, CMR demonstrated improvement in findings after immunosuppressive treatment. However, there was only limited agreement between the degree of high-sensitive troponin levels and T1/T2 levels.
DISCUSSION
CONCLUSIONS
The application of mLLC with T1/T2 mapping appears useful in the CMR diagnosis of acute ICI myocarditis with non-ischaemic myocardial injury criteria being the most common finding. The sensitivity of native T1 appears higher than T2 mapping in the acute diagnosis as well as in the assessment of treatment response. As troponin elevations may persist for some time with ICI myocarditis, CMR may represent an alternate strategy to monitor treatment response.
Identifiants
pubmed: 35079688
doi: 10.1093/ehjcr/ytab478
pii: ytab478
pmc: PMC8783546
doi:
Types de publication
Case Reports
Langues
eng
Pagination
ytab478Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
Circ Cardiovasc Imaging. 2018 Jul;11(7):e007598
pubmed: 30012826
J Cardiovasc Magn Reson. 2019 Aug 29;21(1):54
pubmed: 31462282
J Am Coll Cardiol. 2009 Apr 28;53(17):1475-87
pubmed: 19389557
J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176
pubmed: 30545455
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
J Cardiovasc Magn Reson. 2012 Jun 21;14:42
pubmed: 22720998
JACC Cardiovasc Imaging. 2013 Oct;6(10):1048-1058
pubmed: 24011774
Circ Cardiovasc Imaging. 2012 Jan;5(1):102-10
pubmed: 22038988
Eur Heart J. 2020 May 7;41(18):1733-1743
pubmed: 32112560
JACC CardioOncol. 2020 Dec 15;2(5):800-804
pubmed: 34396297
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828